BTNL10 Inhibitors
BTNL10, or Butyrophilin-like 10, is a transmembrane protein primarily expressed on the surface of antigen-presenting cells, including macrophages and dendritic cells. The protein is implicated in immune regulation and plays a crucial role in modulating T-cell responses. BTNL10's function is associated with the regulation of inflammatory processes and immune tolerance, making it a key player in maintaining immune homeostasis.
The general mechanisms of BTNL10 inhibition involve the modulation of intracellular signaling pathways crucial for immune responses. The identified inhibitors target pathways such as MAPK (Mitogen-Activated Protein Kinase), JAK-STAT (Janus Kinase-Signal Transducer and Activator of Transcription), and PI3K-AKT (Phosphoinositide 3-Kinase-Protein Kinase B). By disrupting these pathways, the inhibitors indirectly influence BTNL10 expression, impacting cellular processes related to inflammation, immune cell activation, and cytokine production. These intricate regulatory networks underscore the complex interplay between BTNL10 and key signaling cascades.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
A pyrimidine synthesis inhibitor that affects the JAK-STAT pathway by inhibiting tyrosine kinases. This disrupts downstream signaling, indirectly influencing BTNL10 by altering the cellular environment. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor targeting the MAPK pathway. By suppressing c-Jun N-terminal kinase activity, it indirectly modulates BTNL10 expression, as JNK is implicated in the regulation of key cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A phosphoinositide 3-kinase (PI3K) inhibitor disrupting the PI3K-AKT-mTOR pathway. This indirect inhibition impacts BTNL10 by altering the PI3K-mediated signaling cascades that converge on BTNL10 regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAP kinase inhibitor affecting the MAPK signaling pathway. This indirect modulation influences BTNL10 expression, as p38 MAP kinase is a key regulator of inflammatory responses and cellular stress. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
A MEK inhibitor disrupting the MAPK/ERK pathway. By inhibiting MEK1/2, it indirectly influences BTNL10 expression, as the MAPK/ERK pathway is involved in cellular proliferation and immune responses. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor blocking the PI3K-AKT pathway. Indirectly, it affects BTNL10 by modulating the PI3K signaling cascade, which plays a role in cell survival, proliferation, and immune responses. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
An inhibitor of NF-κB signaling. By suppressing NF-κB activity, it indirectly modulates BTNL10 expression, as NF-κB is involved in the transcriptional regulation of genes related to inflammation and immunity. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
A JAK2 inhibitor targeting the JAK-STAT pathway. Its indirect influence on BTNL10 involves the inhibition of JAK2, affecting downstream STAT signaling and subsequently altering cellular responses. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
An inhibitor of JAK1 and JAK2. By blocking JAK signaling, it indirectly influences BTNL10 expression, as JAK-STAT pathways play a crucial role in immune responses and inflammatory signaling. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
An AKT kinase inhibitor impacting the PI3K-AKT pathway. Its indirect modulation of BTNL10 involves altering AKT signaling, affecting cellular processes related to immune regulation and inflammatory responses. | ||||||